Receptor activity-modifying protein modulation of parathyroid hormone-1 receptor function and signaling.

biased agonism parathyroid hormone parathyroid hormone receptor-1 parathyroid hormone-related protein receptor-activity-modifying protein

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 26 06 2024
accepted: 03 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 8 10 2024
Statut: epublish

Résumé

Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G-protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH-related protein (PTHrP)-derived ligands. We employed FRET imaging to assess PTH1R interactions with RAMPs. Cell surface expression of PTH1R was evaluated in the presence of RAMPs. PTH1R-mediated cAMP accumulation, β-arrestin recruitment, and calcium signalling were measured in response to various ligands. Antibody-capture scintillation proximity assays were used to examine G-protein activation patterns. PTH1R preferentially interacted with RAMP2 and, to a lesser extent, RAMP3, but not with RAMP1. RAMP3 co-expression reduced cell surface expression of PTH1R. RAMP2 significantly enhanced PTH1R-mediated signalling responses to PTH (1-34), PTHrP (1-34), PTH (1-84), and PTH (1-17) analogue ZP2307, while RAMP3 co-expression attenuated or abolished these responses. Full-length PTHrP analogues exhibited lower potency and efficacy than PTHrP (1-34) in activating PTH1R. RAMP2 increased the potency and/or efficacy of these analogues, whereas RAMP3 reduced these responses. RAMP2 differentially modulated G-protein activation by PTH1R in a ligand-dependent manner, with PTH (1-34) and PTHrP (1-34) inducing distinct patterns of G-protein subtype activation. These findings highlight the complex role of RAMPs in regulating PTH1R signalling and trafficking, revealing differential effects of RAMP2 and RAMP3 on receptor function. The data suggest that targeting the PTH1R/RAMP2 complex may be a promising strategy for developing novel bone anabolic therapies by leveraging biased agonism and functional selectivity. Further research using physiologically relevant models is needed to elucidate the therapeutic potential of this approach.

Identifiants

pubmed: 39376604
doi: 10.3389/fphar.2024.1455231
pii: 1455231
pmc: PMC11456535
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1455231

Informations de copyright

Copyright © 2024 Avgoustou, Jailani, Desai, Roberts, Lilley, Stothard, Skerry and Richards.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Paris Avgoustou (P)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Ameera B A Jailani (ABA)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Aditya J Desai (AJ)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

David J Roberts (DJ)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Ewan R Lilley (ER)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Grant W Stothard (GW)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Timothy M Skerry (TM)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Gareth O Richards (GO)

Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.

Classifications MeSH